Login to Your Account



Study Confirms Zytiga's Benefit in Earlier-Stage Prostate Cancer

By Nuala Moran
Staff Writer

Tuesday, December 11, 2012
Scientists at the Institute of Cancer Research published details of the Phase III trial of Johnson & Johnson's prostate cancer drug Zytiga in men who had not received chemotherapy, a day after the FDA agreed to a label extension allowing the drug to be used at that earlier stage of the disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription